X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
Mavorixafor is an oral, small molecule, CXCR4 antagonist currently being evaluated across three clinical studies: a fully enrolled Phase 3 trial in adults and adolescents with WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome; a Phase 1b clinical trial in adults with chronic neutropenia; and a fully enrolled Phase 1b clinical trial in adults with Waldenström’s macroglobulinemia (WM), a rare B-cell lymphoma.
“We are excited to present new data supporting our ongoing efforts to further elucidate correlations between clinical presentation and new genetic variants associated with WHIM syndrome,” said
- WHIM genetics: Identification of 17 new CXCR4 genetic variants that caused in vitro functional defects resembling those exhibited by known WHIM variants, with potential to enrich current estimates of WHIM syndrome prevalence.
- Development of first cell-based model recapitulating heterozygous CXCR4WT/R334X mutations found in patients with WHIM syndrome, which enriches the toolbox of models available for studying WHIM’s biology and treatment options.
- WM: Study provides preliminary evidence for the potential mechanism of mavorixafor in disrupting the interaction of WM cells with the tumor microenvironment, enhancing the efficacy of B-cell targeted therapies in the treatment of WM and potentially other lymphomas.
Poster Title: Screening of Naturally Occurring CXCR4 Variants for Identification of Novel Pathogenic Mutations for WHIM Syndrome
Poster #: P793
Poster Title: Crispr/Cas9-Based Model of Heterozygous CXCR4WT/R334x Mutation to Study Cellular Phenotypes in WHIM Syndrome
Poster #: P792
Poster Title: Mavorixafor Disrupts the Cross Talk Between Waldenström’s Macroglobulinemia Cells and the Bone Marrow Microenvironment Resulting in Enhanced Sensitivity to B-Cell Targeted Therapies
Poster #: P1253
A copy of the posters will be available on X4’s corporate website at the conclusion of the conference. Additionally, an abstract detailing the 4WHIM Phase 3 trial patient demographics and neutropenia severity has also been accepted for publication only at EHA.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor and X4’s other product candidates or programs; X4’s possible exploration of additional opportunities for mavorixafor; the anticipated achievement of upcoming clinical milestones; the expected availability, content, and timing of clinical trial data; anticipated regulatory filings and commercial plans; clinical trial design, and the company’s cash runway. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development; the risk that trials and studies may be delayed, including, but not limited to, as a result of the effects of the ongoing COVID-19 pandemic or delayed patient enrollment, and may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; risks related to X4’s ability to raise additional capital, and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the
VP, Investor Relations & Corporate Communications
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
Account Supervisor, LifeSci Communications
Source: X4 Pharmaceuticals